title: Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancer.
abstract: In a phase-I-study recombinant interleukin-2 (rIL-2) in a dose from 0.01 to 0.3 mg/m2/day for 7 to 14 days was infused intraperitoneally. Side effects were fever and fluid retention. 2 patients showed a bacterial peritonitis after paracentesis. The investigations showed that the intraperitoneal (i.p.) administration of interleukin-2 activates the whole lymphokine cascade.
authors.affiliation: Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Bertoglio
authors.forename: G
authors.initials: G
authors.lastname: Melioli
authors.forename: E
authors.initials: E
authors.lastname: Baldini
authors.forename: A
authors.initials: A
authors.lastname: Catturich
authors.forename: M R
authors.initials: MR
authors.lastname: Sertoli
authors.forename: D
authors.initials: D
authors.lastname: Civalleri
authors.forename: P
authors.initials: P
authors.lastname: Percivale
authors.forename: W
authors.initials: W
authors.lastname: Meier
authors.forename: A
authors.initials: A
authors.lastname: Galazka
authors.forename: F
authors.initials: F
authors.lastname: Badellino
mesh_terms: D002408:Catheters, Indwelling; D004341:Drug Evaluation; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000628:therapy*; D006801:Humans; D007263:Infusions, Parenteral / Q000295:instrumentation; D007376:Interleukin-2 / Q000008:administration & dosage*; D010051:Ovarian Neoplasms / Q000628:therapy*; D010534:Peritoneal Neoplasms / Q000556:secondary* / Q000628:therapy; D011994:Recombinant Proteins / Q000008:administration & dosage
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins